Systemic sclerosis & Raynaud's
Gut microbiome–metabolome dysregulation in systemic sclerosis: a multi-omics study
Authors' conclusion
This study offers a comprehensive characterization of the disrupted GM-metabolite interface in SSc patients, providing new perspectives on SSc pathogenesis and potential therapeutic targets.
Study context
- Population
- Systemic sclerosis (SSc) patients and healthy controls
- Comparison
- SSc patients vs healthy controls
- Outcome
- Faecal microbiome composition and plasma metabolite profiles
Methodological detailsdeep shotgun metagenomic sequencing, untargeted liquid chromatography-tandem mass spectrometry metabolomic profiling
- Deep shotgun metagenomic sequencing
- Untargeted liquid chromatography-tandem mass spectrometry metabolomic profiling
Main finding
As reported in the abstract
Significantly altered microbial species, SSc vs controls
11
Significantly altered MS2-identified metabolites, SSc vs controls
266
Significant microbiota-metabolite correlations
168
Observational data: associations, not effects.
Original publication
Gut microbiome–metabolome dysregulation in systemic sclerosis: a multi-omics study. Rheumatology (Oxford). Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →